RAS genes are ubiquitous drivers of oncogenesis, found mutated in roughly one-third of all human cancers, including notoriously difficult-to-treat malignancies such as pancreatic, colorectal, and liver cancers. These oncogenes encode molecular switches that regulate cell proliferation; when mutated, they perpetually drive cells toward uncontrolled growth, often culminating in aggressive tumours that defy conventional therapeutics. Although recent advances have yielded drugs targeting some specific RAS mutations, these therapies are limited in scope and efficacy, and resistance mechanisms frequently emerge, highlighting the need for alternative strategies.

The research team investigated the remarkably intensified biochemical demands placed on cancer cells harboring RAS mutations, particularly focusing on the RNA splicing process mediated by the spliceosome. RNA splicing serves as a vital editing step by excising non-coding introns and optimizing messages for protein synthesis. However, in RAS-driven cells, this system becomes overwhelmed due to the accelerated cellular proliferation and increased production of RNA transcripts. By analyzing this critical bottleneck, the researchers have identified that the elevated activity of specific spliceosome components, known as splicing factors, creates an exploitable weakness within RAS-positive cells.

Delving deeper, the team concentrated on oncogene-induced senescence, a state induced by RAS mutations in which cells exit the cell cycle but secrete inflammatory factors damaging the surrounding tissue environment. These senescent cells, marked by their sustained harmful signaling rather than proliferation, contribute to cancer progression and tissue dysfunction. The LMS Senescence Research Group pinpointed two key splicing factors, SF3B1 and RBM39, which are notably upregulated in these senescent RAS-mutant cells. Intriguingly, these factors are targetable by existing pharmacological inhibitors, making them prime candidates for therapeutic intervention.

When these splicing factors were pharmacologically inhibited, the results were striking: RAS-mutant senescent cells were selectively eliminated, and this vulnerability extended beyond senescent populations to various RAS-driven cancer models. These included pre-cancerous lesions and fully developed tumours in the liver, colon, and pancreas. Such findings reveal that the deregulated spliceosome machinery acts as an Achilles’ heel for RAS-mutant cancers, opening a novel and previously unrecognized avenue for combating malignancies long deemed incurable.

Crucially, the research underscores that targeting the RNA splicing machinery with inhibitors against SF3B1 and RBM39 not only halts tumour growth but also reduces tumour size in mouse models. This dual effect hints at a therapeutic potential encompassing both cancer prevention by eliminating premalignant cell clusters and cancer treatment by curbing progression in established malignancies. These promising outcomes spotlight the spliceosome as more than a passive actor in cancer biology but rather a strategic fulcrum with clinical utility.

The significance of this work resonates beyond RAS-driven cancers. Spliceosome deregulation and heightened splicing factor expression have been documented in various tumour types, indicating that spliceosome dependencies might represent a broader hallmark of oncogenic stress adaptation. Nevertheless, the researchers highlight that RAS-mutant cells are uniquely reliant on this system due to their intense metabolic and proliferative demands, making splicing inhibition especially effective in these contexts.

Professor Jesús Gil, senior author and head of the Senescence group at LMS, emphasizes the translational potential of the findings, stating that while the team specializes in fundamental biology rather than drug development, the pre-existence of inhibitors for the identified splicing factors paves the way for collaborations aimed at clinical applications. This foundation could accelerate the repurposing of known drugs into new anti-cancer regimens focused on the spliceosome, circumventing the prolonged timelines typically necessary for novel drug discovery.

In addition to providing a new therapeutic target, the research enriches the understanding of tumour biology by illuminating how cancer cells’ intrinsic stress responses, such as senescence and splicing overload, can be co-opted into treatment strategies. By exploiting the cellular coping mechanisms themselves, researchers offer a paradigm shift from targeting cancer cells solely on their proliferative capacity to dismantling their essential housekeeping operations responsible for RNA processing and protein synthesis.

The study represents an international scientific collaboration inclusive of the LMS, Imperial College London, the University of Lisbon, and University Hospital Tübingen, embodying the collective efforts needed to tackle complex oncogenic processes. Supported by the Medical Research Council and Cancer Research UK, this research propels a promising frontier in molecular oncology where mastery over fundamental RNA biology intersects with clinical oncology.

While further studies are necessary to elaborate upon dosing regimens and potential combinatory therapies, the identification of the spliceosome as a druggable dependency underscores an exciting frontier. It invites additional exploration into the interplay between senescence, RNA splicing, and oncogenic signaling, fostering hope for improved therapeutic outcomes against cancers fueled by RAS mutations, and potentially others that share similar molecular vulnerabilities.

Ultimately, these findings challenge the status quo of cancer therapy by positing that undermining the RNA processing machinery could serve as a lethal blow to tumour cells, striking at the heart of their metabolic and proliferative demands. This innovative approach may soon offer patients diagnosed with historically intractable RAS-driven cancers a novel lifeline, transforming one of oncology’s most formidable challenges into a treatable condition.

Subject of Research: Cellular machinery vulnerabilities in RAS-driven cancers and targeting spliceosome components.

Article Title: Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer.

News Publication Date: 15-Apr-2026.

Web References: http://dx.doi.org/10.1038/s41467-026-71564-z

Image Credits: Laura Bousset, MRC Laboratory of Medical Sciences.

Keywords: RAS oncogenes, spliceosome, cellular senescence, splicing factors, SF3B1, RBM39, cancer therapeutics, RNA processing, tumour vulnerability, senescence-induced cancer, molecular oncology.

Copper is fundamental for numerous biochemical pathways, acting as a critical cofactor in enzymatic reactions required for cell survival. However, it demands a rigorously maintained intracellular balance, as any departure from homeostasis can have profound effects. Dysregulation of copper in RCC has long been suspected to play a pivotal role in oncogenesis, yet the detailed molecular underpinnings have remained obscure. Emerging evidence places cuproptosis—a novel form of programmed cell death triggered by copper accumulation—at the vanguard of innovative cancer therapies. Simultaneously, cuproplasia describes copper-driven cell proliferation, fostering tumor growth. Understanding where the line is drawn between these opposing outcomes remains an exhilarating frontier.

A core challenge lies in determining the precise threshold of copper concentrations that shifts cellular fate from survival and proliferation to irreversible death. This threshold is not merely a quantitative measure; it reflects the intricate network of molecular switches that regulate copper’s dualistic influence on RCC cells. Decoding these regulatory nodes offers unprecedented opportunities to exploit copper’s cytotoxic potential while curtailing its tumor-promoting effects. Yet, definitive experimental data pinpointing this threshold remain absent, compelling researchers to probe deeper into the molecular circuits modulating copper-dependent cellular states.

The current research landscape is increasingly leveraging machine learning and sophisticated bioinformatics approaches to unravel copper’s multifaceted roles in RCC. Computational models examining cuproptosis-linked gene signatures have revealed promising correlations with clinical outcomes, underscoring the potential prognostic and predictive value of copper-regulated pathways. However, this surge in in silico data necessitates rigorous experimental validation to translate theoretical models into tangible clinical interventions. Bridging this gap between computational predictions and laboratory findings forms the cornerstone of advancing copper-based oncology therapies.

Although the concept of copper inducing cuproplasia—a pro-tumorigenic process—is still largely hypothetical, its implications in RCC are profound. Experimental validation is urgently needed to elucidate how copper-driven proliferation specifically contributes to the heterogeneity in RCC subtypes. Furthermore, unraveling the association between copper-mediated processes and mechanisms of drug resistance in RCC cells could illuminate new avenues to bypass therapeutic obstacles. The metabolic reprogramming induced by fluctuating copper levels presents another tantalizing aspect, potentially altering tumor bioenergetics to sustain malignancy.

The tumor immune microenvironment (TME) is an additional domain where copper’s role remains enigmatic but potentially transformative. Copper’s interaction with immune cells infiltrating RCC tumors might mediate immune evasion or provide susceptibility to immune checkpoint inhibitors. Deciphering these interactions will be crucial for integrating copper-centered treatments with contemporary immunotherapies, thereby enhancing their efficacy and specificity. The identification of key genes orchestrating RCC progression through copper-dependent pathways also remains a priority, offering molecular targets for drug development.

Clinical trials investigating copper-based therapies in RCC are nascent yet promising. Preclinical models consistently demonstrate copper’s ambivalent nature—exerting oncogenic influence under certain contexts while promoting cytotoxicity under others. This duality suggests that future clinical protocols must adopt combination strategies, potentially pairing copper modulators with established agents such as VEGF inhibitors, which have revolutionized RCC treatment. Likewise, combining copper-directed agents with immune checkpoint blockade could harness synergistic effects, optimizing patient outcomes through personalized therapeutic regimens.

The lack of precise, experimentally validated biomarkers that can predict when copper’s influence shifts from tumorigenic to tumoricidal complicates both research and clinical translation. Developing such biomarkers will be instrumental in patient stratification, allowing clinicians to identify individuals who would most benefit from copper-targeted interventions. Likewise, understanding the spatiotemporal dynamics of copper homeostasis within RCC tissues could illuminate new intervention points, offering a window into tailoring treatments based on tumor microenvironmental cues.

Recent advances in molecular biology techniques, including CRISPR-based gene editing and advanced imaging modalities, equip researchers with unprecedented tools to dissect copper-related pathways at cellular and subcellular resolution. Such approaches will enable precise manipulation of copper transporters, chaperones, and cuproptosis regulators, thereby refining our understanding of copper-induced cellular phenomena. Moreover, integration with metabolomics and proteomics datasets will unravel copper’s broad impact on cellular metabolism and proteostasis, further enriching the molecular narrative.

Understanding the fundamental biochemical framework of cuproptosis is vital, as this newly characterized cell death mechanism diverges significantly from classical apoptosis, necroptosis, and ferroptosis. Cuproptosis is closely tied to mitochondrial function, particularly in relation to iron-sulfur cluster proteins and lipoylated components of the tricarboxylic acid (TCA) cycle. Disruptions in these mitochondrial processes via copper overload trigger lethal proteotoxic stress, culminating in cell demise. This mechanism offers a unique vulnerability in RCC cells reliant on oxidative phosphorylation, presenting a stark contrast to glycolysis-dependent tumors where copper’s role might be less pronounced.

Conversely, cuproplasia encapsulates copper’s capacity to fuel cellular proliferation, amplifying oncogenic signaling pathways that promote growth and survival. The molecular determinants tipping the balance toward this proliferative state—including potential feedback loops and checkpoint regulators—remain undefined. Addressing these knowledge gaps would allow researchers to manipulate copper flux within tumors tactically, ideally suppressing proliferative cues while inducing cuproptotic cell death.

The translational potential of copper-directed therapies extends beyond RCC, capturing interest across various malignancies characterized by aberrant copper metabolism. The dualistic nature of copper offers a therapeutic window that, if precisely targeted, could selectively eliminate cancer cells while sparing normal tissue. However, the challenge lies in designing agents with fine specificity for copper homeostasis components—transporters, storage proteins, or chaperones—limiting off-target toxicity. The dynamic and context-dependent behavior of copper in tumors underscores the necessity for integrating molecular profiling into treatment planning.

Continued research is expected to redefine the role of copper in RCC through multidisciplinary collaborations, merging computational predictions with mechanistic studies and clinical explorations. As the field progresses, it is likely that effective copper modulators will complement the current arsenal of targeted therapies and immunotherapies, contributing to precision oncology paradigms where treatment is tailored to the unique copper metabolism status of individual tumors. This new horizon offers hope for overcoming RCC’s therapeutic resistance and improving patient survival rates.

In conclusion, the dual roles of copper in promoting cell proliferation and triggering a distinct form of programmed cell death expose an intricate balance ripe for therapeutic exploitation. While computational and preclinical data have illuminated the possibilities, the field stands at a critical juncture requiring robust experimental validation and carefully designed clinical trials. By elucidating the molecular switches that govern cuproptosis and cuproplasia, and innovatively combining copper-based agents with existing therapies, the oncology community may unlock a new frontier in RCC treatment, with broader implications across cancer biology.

Subject of Research: Understanding the roles of copper-induced cuproptosis and cuproplasia in renal cell carcinoma to develop targeted therapeutic strategies.

Article Title: Decoding cuproptosis and cuproplasia: implications for therapeutic strategies in renal cell carcinoma

Article References:
Abraham Gnanadass, S., Pandey, S. & Viswanathan, P. Decoding cuproptosis and cuproplasia: implications for therapeutic strategies in renal cell carcinoma.
Cell Death Discov. 11, 501 (2025). https://doi.org/10.1038/s41420-025-02734-z

DOI: 10.1038/s41420-025-02734-z

Image Credits: AI Generated

At the molecular level, fusion genes often encode aberrant fusion proteins with unique domain architectures that co-opt signaling pathways critical for cell growth, survival, and differentiation. Unlike normal proteins, these chimeric entities can constitutively activate oncogenic cascades, dismantle tumor suppressor functions, and reprogram cellular metabolism. For instance, the BCR-ABL fusion protein, archetypal in chronic myeloid leukemia, combines the breakpoint cluster region (BCR) with the Abelson tyrosine kinase (ABL), resulting in constitutive tyrosine kinase activity that drives unchecked proliferation. Similarly, fusion proteins like EML4-ALK in non-small cell lung cancer and PML-RARα in acute promyelocytic leukemia catalyze oncogenesis via distinct yet potent mechanisms, exemplifying the functional diversity and tissue specificity of fusion oncogenes.

The discovery and characterization of these fusion genes have revolutionized cancer diagnostics. Advanced genomic technologies, including next-generation sequencing (NGS) and RNA sequencing (RNA-seq), now enable the precise identification of fusion transcripts with remarkable sensitivity. This molecular precision facilitates the stratification of tumors beyond histopathological criteria, permitting clinicians to delineate subtypes with differential prognoses and therapeutic vulnerabilities. Moreover, the advent of liquid biopsy techniques empowers real-time monitoring of fusion gene burden in circulating tumor DNA or RNA, providing minimally invasive windows into tumor evolution and therapeutic response dynamics.

Therapeutically, fusion genes represent a golden target. The development of targeted inhibitors against fusion proteins, such as tyrosine kinase inhibitors (TKIs) targeting BCR-ABL or ALK fusions, have dramatically altered clinical outcomes in affected patient populations. These agents afford enhanced efficacy with reduced systemic toxicity compared to conventional cytotoxic chemotherapies. However, the clinical journey is not without challenges. Resistance mechanisms mediated by secondary mutations, activation of compensatory pathways, or phenotypic plasticity pose formidable obstacles that necessitate continual drug development and combination strategies to sustain remission and prevent relapse.

A critical frontier remains in understanding the functional heterogeneity of fusion genes and their contextual interactions within the tumor microenvironment. This complexity influences cancer aggressiveness, immune evasion, and metastatic propensity. Emerging research is elucidating how fusion proteins modulate cell-cell communication, extracellular matrix remodeling, and immune checkpoint landscapes, underscoring the multifaceted roles these genetic alterations play beyond autonomous tumor cell proliferation. Deciphering these intricate networks will be pivotal for bespoke interventions in resistant or refractory cancers.

Notably, the biogenesis of fusion genes involves a spectrum of genomic instability processes. DNA double-strand breaks, erroneous repair via non-homologous end joining (NHEJ), and replication stress contribute to chromosomal rearrangements that generate fusion transcripts. The landscape of fusion gene formation is further complicated by the presence of complex structural variants and cryptic rearrangements often elusive to routine cytogenetic analysis. Enhanced bioinformatic pipelines and integrative omics approaches are thus essential to capturing the full spectrum of fusion events and their oncogenic consequences.

Immense promise lies in the deployment of next-generation inhibitors tailored to specific fusion-driven malignancies. Structural biology and high-throughput screening are expediting the discovery of agents capable of targeting unique fusion protein interfaces or downstream effectors. Additionally, combinatorial therapeutic regimens that integrate fusion protein inhibition with immunotherapy, epigenetic modulators, or metabolic interventions hold significant potential in overcoming resistance and achieving durable remissions.

The clinical translation of fusion gene research also benefits from refined diagnostic assays designed for rapid detection and quantification. Multiplexed PCR assays, fluorescence in situ hybridization (FISH), and emerging CRISPR-based diagnostics enhance the clinical laboratory toolkit, enabling timely therapeutic decision-making. Coupling these technologies with artificial intelligence-driven predictive models further augments the precision medicine paradigm, optimizing individual patient management.

Importantly, the implications of fusion genes extend beyond oncology. Their roles in developmental disorders, congenital abnormalities, and other disease states are subjects of active investigation, suggesting a broader biological significance. Understanding fusion gene biology may reveal novel pathogenic mechanisms and therapeutic targets across diverse medical disciplines.

Despite remarkable advancements, the field confronts unresolved challenges. Heterogeneity within and between tumor types, the temporal dynamics of fusion gene expression during disease progression, and the interplay with host genomic and epigenomic landscapes require elucidation. Addressing these gaps through multidisciplinary collaboration and innovative research methodologies will accelerate the realization of fusion gene-targeted therapies as standard of care.

In summation, fusion genes stand as linchpins in the molecular architecture of many cancers, offering both profound insights into tumorigenesis and actionable therapeutic targets. The fusion of cutting-edge genomic technologies with drug innovation portends a transformative impact on cancer care, aligning with the overarching objectives of precision medicine. As the molecular taxonomy of cancers is refined, fusion genes will undoubtedly remain at the vanguard of translational oncology, offering renewed hope to patients worldwide.

Subject of Research: Fusion genes in cancer

Article Title: Fusion genes in cancers: Biogenesis, functions, and therapeutic implications

News Publication Date: 2025

References: Haiqiong Tang, Qiu Peng, Linda Oyang, Shiming Tan, Xianjie Jiang, Zongyao Ren, Xuemeng Xu, Mengzhou Shen, Haofan Li, Mingjing Peng, Longzheng Xia, Wenjuan Yang, Shizhen Li, Jiewen Wang, Yaqian Han, Nayiyuan Wu, Yanyan Tang, Jinguan Lin, Qianjin Liao, Yujuan Zhou, Fusion genes in cancers: Biogenesis, functions, and therapeutic implications, Genes & Diseases, Volume 12, Issue 5, 2025, 101536

Image Credits: Genes & Diseases

Keywords: Cancer genetics, Fusion genes, Oncogenes, Precision medicine, Targeted therapy